3-methoxytyrosine has been researched along with Parkinson Disease in 61 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 9.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "A short-term, randomized, partly blinded, crossover, investigator-initiated clinical trial was performed, with levodopa/carbidopa intestinal gel combined with oral entacapone and tolcapone on two different days in 10 patients." | 6.77 | Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. ( Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D, 2012) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 5.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 5.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "A paucity of information is available concerning the use of levodopa and carbidopa during pregnancy." | 5.08 | Human transplacental transfer of carbidopa/levodopa. ( Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD, 1995) |
| "A short-term, randomized, partly blinded, crossover, investigator-initiated clinical trial was performed, with levodopa/carbidopa intestinal gel combined with oral entacapone and tolcapone on two different days in 10 patients." | 2.77 | Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. ( Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D, 2012) |
| " Levodopa bioavailability was higher on day 2 due to the COMT inhibition." | 2.76 | Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. ( Muhlack, S; Müller, T; Woitalla, D, 2011) |
| " We compared the motor response after once dosing of 200 mg retarded release LD (levodopa)/CD (carbidopa) and of 150 mg LD/CD/EN (entacapone) by rating of motor symptoms, by measurement of LD- and 3-O-methyldopa (3-OMD) plasma concentrations and by the outcomes of a line tracing task." | 2.73 | Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. ( Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D, 2007) |
| " Not optimum treated hospitalised patients with Parkinson's disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t." | 2.72 | Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. ( Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D, 2006) |
| " Long-term levodopa administration results in an increased levodopa plasma bioavailability in PD patients." | 2.71 | Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. ( Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D, 2004) |
| " The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1." | 2.69 | Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ( Crevoisier, C; Dingemanse, J; Gasser, UE; Kleinbloesem, CH; Lankhaar, G, 1998) |
| "When tolcapone was combined with 25 mg benserazide the elevation was small." | 2.69 | The effect of tolcapone on the pharmacokinetics of benserazide. ( Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M, 1999) |
| " The advantage of the Dixon equation over the sigmoid equation is that the Dixon equation can take 3OMD into consideration for pharmacodynamic modelling." | 2.69 | Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation. ( Furlanut, M; Wu, G, 1999) |
| "Thus entacapone seems to be a valuable adjuvant to levodopa treatment in parkinsonian patients with end-of-dose failure." | 2.68 | Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ( Rinne, UK; Ruottinen, HM, 1996) |
| "The effects of tolcapone, a catechol-O-methyltransferase inhibitor, on the bioavailability and efficacy of levodopa were evaluated in 12 patients with Parkinson's disease (PD), 8 of whom showed signs of daily motor fluctuations (wearing-off phenomenon)." | 2.68 | Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. ( Hattori, Y; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Narabayashi, H; Tohgi, H; Tsukamoto, Y; Yamamoto, M; Yanagisawa, N; Yokochi, M, 1997) |
| " These patients required a higher total daily dosage of Sinemet CR than of Sinemet for control of parkinsonian symptoms, but less frequent dosing was required during chronic therapy." | 2.66 | Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ( August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC, 1989) |
| " In 19 parkinsonians with prominent dose-by-dose fluctuations, double-blind crossover trials comparing 8-week regimens of standard carbidopa/levodopa (25/100) to Sinemet CR (50/200) showed comparable clinical outcomes, with mean daily dosing for optimal control reduced from 10." | 2.66 | Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ( Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P, 1989) |
| " Low levodopa dosing and antioxidants in the rotigotine patch matrix prevented cysteinyl-glycine fall." | 1.46 | Levodopa, placebo and rotigotine change biomarker levels for oxidative stress. ( Herrman, L; Kinkel, M; Muhlack, S; Müller, T, 2017) |
| "Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy." | 1.39 | Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ( Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA, 2013) |
| "Fifteen patients with Parkinson's disease orally took one 200-mg levodopa/50-mg carbidopa (CD) containing tablet." | 1.37 | Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. ( Muhlack, S; Müller, T, 2011) |
| "Patients with Parkinson's disease (PD) received on two consecutive days in a standardised fashion one single dose of 200 mg retarded release LD/carbidopa (CD) or of 150 mg LD/CD/EN, since both were shown to have simultaneous pharmacokinetic LD behaviour." | 1.35 | Peripheral COMT inhibition prevents levodopa associated homocysteine increase. ( Muhlack, S; Müller, T, 2009) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| "We characterized the clinical dose-response curves for relief of parkinsonism and production of dyskinesias as a function of plasma levodopa and 3-O-methyldopa levels in six patients with advanced Parkinson's disease (PD) and fluctuating responses to oral levodopa/carbidopa." | 1.29 | Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. ( Bennett, JP; Schuh, LA, 1993) |
| "Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake." | 1.29 | Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. ( Belakhlef, A; Chaly, T; Dahl, R; Dhawan, V; Eidelberg, D; Ishikawa, T; Mandel, F; Margouleff, C; Robeson, W, 1996) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 1.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| " Total daily levodopa intake was greater with Sinemet CR, although the bioavailability of levodopa and carbidopa from the two preparations was equivalent." | 1.28 | A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). ( Cedarbaum, JM; Kutt, H; McDowell, FH, 1989) |
| "5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10." | 1.28 | Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability. ( Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R, 1989) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily levodopa dosage and do not vary markedly during the day." | 1.27 | 3-O-methyldopa and the response to levodopa in Parkinson's disease. ( Gancher, ST; Merrick, D; Nutt, JG; Woodward, WR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (27.87) | 18.7374 |
| 1990's | 24 (39.34) | 18.2507 |
| 2000's | 12 (19.67) | 29.6817 |
| 2010's | 8 (13.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muhlack, S | 8 |
| Kinkel, M | 1 |
| Herrman, L | 1 |
| Müller, T | 10 |
| Kuhn, W | 2 |
| Adamiak, U | 1 |
| Kaldonska, M | 1 |
| Klodowska-Duda, G | 1 |
| Wyska, E | 1 |
| Safranow, K | 1 |
| Bialecka, M | 1 |
| Gawronska-Szklarz, B | 1 |
| Woitalla, D | 5 |
| Ishihara, A | 1 |
| Miyachi, T | 1 |
| Nakamura, T | 1 |
| Ohtsuki, T | 1 |
| Kimura, Y | 2 |
| Kihira, K | 2 |
| Yamawaki, T | 1 |
| Matsumoto, M | 1 |
| Nyholm, D | 2 |
| Johansson, A | 2 |
| Lennernäs, H | 1 |
| Askmark, H | 1 |
| Onzawa, Y | 1 |
| Uzuhashi, K | 1 |
| Shirasuna, M | 1 |
| Hirosawa, T | 1 |
| Taogoshi, T | 1 |
| Odin, P | 1 |
| Chatamra, K | 1 |
| Locke, C | 1 |
| Dutta, S | 1 |
| Othman, AA | 1 |
| Blandini, F | 5 |
| Nappi, G | 5 |
| Fancellu, R | 2 |
| Mangiagalli, A | 2 |
| Samuele, A | 2 |
| Riboldazzi, G | 1 |
| Calandrella, D | 1 |
| Pacchetti, C | 4 |
| Bono, G | 1 |
| Martignoni, E | 5 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Welnic, J | 2 |
| Twiehaus, S | 1 |
| Przuntek, H | 2 |
| Erdmann, C | 1 |
| Bremen, D | 1 |
| Goetze, O | 1 |
| Ander, L | 1 |
| Kolf, K | 1 |
| Mena, MA | 1 |
| Aguado, EG | 2 |
| de Yebenes, JG | 2 |
| Beers, MF | 1 |
| Stern, M | 1 |
| Hurtig, H | 1 |
| Melvin, G | 1 |
| Scarpa, A | 1 |
| Ishimitsu, T | 2 |
| Hirose, S | 2 |
| Asahara, K | 1 |
| Imaizumi, M | 1 |
| Gervas, JJ | 1 |
| Muradás, V | 1 |
| Bazán, E | 1 |
| Prasad, AL | 1 |
| Fahn, S | 2 |
| Reches, A | 1 |
| Tohgi, H | 4 |
| Abe, T | 3 |
| Yamazaki, K | 1 |
| Saheki, M | 1 |
| Takahashi, S | 3 |
| Tsukamoto, Y | 2 |
| Moser, A | 2 |
| Scholz, J | 1 |
| Nobbe, F | 1 |
| Vieregge, P | 2 |
| Böhme, V | 1 |
| Bamberg, H | 1 |
| Spencer, JP | 1 |
| Jenner, A | 1 |
| Aruoma, OI | 1 |
| Evans, PJ | 1 |
| Kaur, H | 1 |
| Dexter, DT | 1 |
| Jenner, P | 1 |
| Lees, AJ | 2 |
| Marsden, DC | 1 |
| Halliwell, B | 1 |
| Schuh, LA | 1 |
| Bennett, JP | 1 |
| Benetello, P | 1 |
| Furlanut, M | 2 |
| Zara, G | 1 |
| Baraldo, M | 1 |
| Hassan, E | 1 |
| Nutt, JG | 2 |
| Carter, JH | 1 |
| Woodward, W | 1 |
| Hammerstad, JP | 1 |
| Gancher, ST | 2 |
| Merchant, CA | 1 |
| Cohen, G | 1 |
| Mytilineou, C | 1 |
| DiRocco, A | 1 |
| Moros, D | 1 |
| Molinari, S | 1 |
| Yahr, MD | 1 |
| Ruottinen, HM | 1 |
| Rinne, UK | 1 |
| Ishikawa, T | 1 |
| Dhawan, V | 1 |
| Chaly, T | 1 |
| Robeson, W | 1 |
| Belakhlef, A | 1 |
| Mandel, F | 1 |
| Dahl, R | 1 |
| Margouleff, C | 1 |
| Eidelberg, D | 1 |
| O'Connell, MT | 1 |
| Tison, F | 1 |
| Quinn, NP | 1 |
| Patsalos, PN | 1 |
| Yamamoto, M | 1 |
| Yokochi, M | 1 |
| Kuno, S | 1 |
| Hattori, Y | 1 |
| Narabayashi, H | 1 |
| Mizuno, Y | 1 |
| Kowa, H | 1 |
| Yanagisawa, N | 1 |
| Kanazawa, I | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Krygowska-Wajs, A | 1 |
| Szczudlik, A | 1 |
| Romańska, I | 1 |
| Vetulani, J | 1 |
| Desideri, S | 2 |
| Rivellini, D | 1 |
| Dingemanse, J | 1 |
| Kleinbloesem, CH | 1 |
| Crevoisier, C | 1 |
| Lankhaar, G | 1 |
| Gasser, UE | 1 |
| Siebecker, F | 1 |
| Jaskowski, P | 1 |
| Kömpf, D | 1 |
| Jorga, KM | 1 |
| Larsen, JP | 1 |
| Beiske, A | 1 |
| Schleimer, M | 1 |
| Fotteler, B | 1 |
| Schmitt, M | 1 |
| Moe, B | 1 |
| Liu, H | 1 |
| Iacono, RP | 1 |
| Schoonenberg, T | 1 |
| Kuniyoshi, S | 1 |
| Buchholz, J | 1 |
| Wu, G | 1 |
| Godi, L | 1 |
| Mancini, F | 1 |
| Ricotti, R | 1 |
| di Jeso, F | 1 |
| Soares-da-Silva, P | 1 |
| Parada, A | 1 |
| Serrão, P | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Fowler, B | 1 |
| Maruyama, W | 1 |
| Naoi, M | 1 |
| Takahashi, A | 1 |
| Watanabe, H | 1 |
| Konagaya, Y | 1 |
| Mokuno, K | 1 |
| Hasegawa, S | 1 |
| Nakahara, D | 1 |
| Kikuchi, T | 2 |
| Nozaki, Y | 2 |
| Cedarbaum, JM | 3 |
| Leger, G | 1 |
| Guttman, M | 1 |
| Kutt, H | 2 |
| McDowell, FH | 2 |
| Yeh, KC | 1 |
| August, TF | 1 |
| Bush, DF | 1 |
| Lasseter, KC | 1 |
| Musson, DG | 1 |
| Schwartz, S | 1 |
| Smith, ME | 1 |
| Titus, DC | 1 |
| LeWitt, PA | 1 |
| Nelson, MV | 1 |
| Berchou, RC | 1 |
| Galloway, MP | 1 |
| Kesaree, N | 1 |
| Kareti, D | 1 |
| Schlick, P | 1 |
| Luquin, MR | 1 |
| Vaamonde, J | 1 |
| Obeso, JA | 1 |
| Contin, M | 1 |
| Riva, R | 1 |
| Martinelli, P | 1 |
| Procaccianti, G | 1 |
| Baruzzi, A | 1 |
| Boomsma, F | 1 |
| Meerwaldt, JD | 1 |
| Man in't Veld, AJ | 1 |
| Hovestadt, A | 1 |
| Schalekamp, MA | 1 |
| Hardie, RJ | 1 |
| Malcolm, SL | 1 |
| Stern, GM | 1 |
| Allen, JG | 1 |
| Fabbrini, G | 1 |
| Juncos, JL | 1 |
| Mouradian, MM | 1 |
| Serrati, C | 1 |
| Chase, TN | 1 |
| Woodward, WR | 1 |
| Merrick, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease[NCT01484990] | Phase 1 | 19 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 trials available for 3-methoxytyrosine and Parkinson Disease
| Article | Year |
|---|---|
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Huma | 2009 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; | 2010 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; C | 2011 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechols; Cross-Over Studies; | 2012 |
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Biological A | 2004 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pres | 2006 |
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Down-Regulation; Enzyme Inhibitors; Humans; Hydrocortisone; | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind M | 2007 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Mater | 1995 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dou | 1996 |
Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Area Under Curve; Drug Monitoring; Half-Life; Humans; Levodopa; Microdialysis; | 1996 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors | 1997 |
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
Topics: Adult; Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dementia; Female; Homovanil | 1997 |
Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Female; Fo | 1998 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Admin | 1999 |
Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation.
Topics: Aged; Drug Interactions; Female; Humans; Levodopa; Male; Models, Statistical; Parkinson Disease; Tyr | 1999 |
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
Topics: Antiparkinson Agents; Biomarkers; Blood Platelets; Dopamine; Female; Gentisates; Humans; Hydroxybenz | 1999 |
Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electrochemistry | 1999 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials a | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double | 1989 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; | 1988 |
The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
Topics: Absorption; Administration, Oral; Adult; Carboxy-Lyases; Clinical Trials as Topic; Dose-Response Rel | 1986 |
39 other studies available for 3-methoxytyrosine and Parkinson Disease
| Article | Year |
|---|---|
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides | 2017 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibi | 2009 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Carbidopa; Dipeptides; Female; Humans; Levodopa; Male; O | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 2011 |
Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Mo | 2012 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinatio | 2013 |
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Benzophenones; Blood Platelets; Catechols; Do | 2003 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
Topics: Adult; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Epinephrine; Humans; | 1984 |
The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Dopamine; Humans; Levodopa; Methyltyrosines; Parkinson Disease; Tyrosine | 1984 |
Effects of 3-OM-dopa on monoamine metabolism in rat brain.
Topics: alpha-Methyltyrosine; Animals; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Levodopa; | 1983 |
A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients.
Topics: Autoanalysis; Dihydroxyphenylalanine; Erythrocytes; Humans; Levodopa; Methyltyrosines; Parkinson Dis | 1982 |
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug | 1982 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Met | 1995 |
Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease.
Topics: Adult; Aged; Cerebrospinal Fluid Proteins; Dopamine; Female; Homovanillic Acid; Humans; Isoquinoline | 1995 |
Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.
Topics: Brain Chemistry; Catalysis; Copper; DNA; DNA Damage; Dopamine; Humans; Hydrogen Peroxide; Iron; Levo | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dru | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed- | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; | 1993 |
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Topics: Adult; Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Chromatography, High Pressure Liqui | 1996 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Aged; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electroche | 1997 |
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations | 1996 |
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progressi | 1999 |
The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Cells, Cultu | 2000 |
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |
3-OMD and homocysteine plasma levels in parkinsonian patients.
Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.
Topics: Aged; Amino Acids; Animals; Biogenic Monoamines; Corpus Striatum; Dialysis; Dopamine; Female; Humans | 1992 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Topics: Biogenic Monoamines; Biomarkers; Carbidopa; Humans; Levodopa; Middle Aged; Parkinson Disease; Tyrosi | 1991 |
Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
Topics: Aged; Dihydroxyphenylalanine; Dopamine; Humans; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Levodopa; Macaca fascicularis; Male; Ni | 1991 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Par | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Di | 1989 |
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
Topics: Aged; Aged, 80 and over; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Human | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Co | 1989 |
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle A | 1987 |
3-O-methyldopa and the response to levodopa in Parkinson's disease.
Topics: Administration, Oral; Blood-Brain Barrier; Humans; Infusions, Intravenous; Levodopa; Parkinson Disea | 1987 |
Determination of m- and p-O-methylated products of L-3,4-dihydroxyphenylalanine using high-performance liquid chromatography and electrochemical detection.
Topics: Animals; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Electrochemistry; Human | 1985 |